Cargando…

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity

BACKGROUND: Adenovirus serotype 5 (Ad5) is a commonly used viral vector for transient delivery of transgenes, primarily for vaccination against pathogen and tumor antigens. However, endemic infections with Ad5 produce virus-specific neutralizing antibodies (NAbs) that limit transgene delivery and co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flickinger Jr, John C, Singh, Jagmohan, Carlson, Robert, Leong, Elinor, Baybutt, Trevor R, Barton, Joshua, Caparosa, Ellen, Pattison, Amanda, Rappaport, Jeffrey A, Roh, Jamin, Zhan, Tingting, Bashir, Babar, Waldman, Scott A, Snook, Adam E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443303/ https://www.ncbi.nlm.nih.gov/pubmed/32819976 http://dx.doi.org/10.1136/jitc-2020-001046

Ejemplares similares

GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress
por: Kraft, Crystal L., et al.
Publicado: (2017)

APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis
por: Blomain, Erik S., et al.
Publicado: (2020)

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
por: Flickinger, John C., et al.
Publicado: (2022)

GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
por: Magee, Michael S., et al.
Publicado: (2016)

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
por: Snook, Adam E., et al.
Publicado: (2019)

Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity
por: Pattison, Amanda M., et al.
Publicado: (2020)

A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
por: Snook, Adam, et al.
Publicado: (2015)

GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity
por: Lin, Jieru Egeria, et al.
Publicado: (2012)

Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
por: Su, Yinghan, et al.
Publicado: (2022)

GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer
por: Magee, Michael S, et al.
Publicado: (2013)

GUCY2C at the intersection of obesity and colorectal cancer
por: Waldman, Scott A, et al.
Publicado: (2013)

GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults
por: Cheslow, Lara, et al.
Publicado: (2023)

GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
por: Marszalowicz, Glen P., et al.
Publicado: (2014)

Intestinal neuropod cell GUCY2C regulates visceral pain
por: Barton, Joshua R., et al.
Publicado: (2023)

Hormone suppression silencing GUCY2C is required for colorectal cancer
por: Waldman, Scott A
Publicado: (2015)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer
por: Rappaport, Jeffrey A., et al.
Publicado: (2021)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

The Guanylate Cyclase C—cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia
por: Rappaport, Jeffrey A., et al.
Publicado: (2018)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses
por: Koodie, Lisa, et al.
Publicado: (2019)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Serotype Chimeric Human Adenoviruses for Cancer Gene Therapy
por: Ranki, Tuuli, et al.
Publicado: (2010)

First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
por: Wang, Shujing, et al.
Publicado: (2021)

T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
por: Flickinger, John C., et al.
Publicado: (2022)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

The grim reaper evading modern medicine: aspergillosis, adenovirus, and Hodgkin lymphoma
por: Nichols, Larry, et al.
Publicado: (2020)

ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice
por: Li, Peng, et al.
Publicado: (2017)

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
por: Sun, Ming-Yao, et al.
Publicado: (2023)

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
por: Liu, Fangming, et al.
Publicado: (2020)

Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
por: Rampuria, Pragya, et al.
Publicado: (2023)

Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
por: Arnone, Claudia Manuela, et al.
Publicado: (2021)

Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35
por: Zhang, Wen-feng, et al.
Publicado: (2016)

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
por: Ang, Zhiwei, et al.
Publicado: (2023)

Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition
por: Lu, Ling, et al.
Publicado: (2023)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Poly-Gamma-Glutamic Acid (γ-PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies
por: Khalil, Ibrahim R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5hmcplh22fqaddad0kl7ffarkc